Drug Patents Expiring in 2031

1. Abilify Mycite Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229378 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jul, 2031

(6 years from now)

US9320455 OTSUKA Highly reliable ingestible event markers and methods for using the same
Dec, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

2. Accrufer patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148 SHIELD TX Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: 26 July, 2023

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE

More Information on Dosage

ACCRUFER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Acetadote patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9327028 CUMBERLAND PHARMS Acetylcysteine compositions and methods of use thereof
Jul, 2031

(6 years from now)




Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

4. Adlyxin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8882721 SANOFI-AVENTIS US Drive assembly suitable for use in a drug delivery device and drug delivery device
Jun, 2031

(6 years from now)

US9084853 SANOFI-AVENTIS US Drive mechanism for a drug delivery device and drug delivery device
Oct, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ADLYXIN family patents

Family Patents

5. Afrezza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358352 MANNKIND Dry powder drug delivery system and methods
Feb, 2031

(6 years from now)

US8227409 MANNKIND Diketopiperazine microparticles with defined isomer contents
Mar, 2031

(6 years from now)

US9597374 MANNKIND Use of ultrarapid acting insulin
Oct, 2031

(6 years from now)

US8424518 MANNKIND Dry powder inhaler and system for drug delivery
Oct, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 27, 2017

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 June, 2014

Treatment: Use of an inhaler to administer dry powder medicament; Administration of fdkp microparticles comprising insulin.; Method of controlling glycemia in diabetics by administering an initial dose of insuli...

Dosage: POWDER

More Information on Dosage

AFREZZA family patents

Family Patents

6. Airduo Digihaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(6 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(6 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(6 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(6 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(6 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(6 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

7. Airduo Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(6 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(6 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(6 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(6 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(6 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(6 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

More Information on Dosage

AIRDUO RESPICLICK family patents

Family Patents

8. Akeega patent expiration

AKEEGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8071623 JANSSEN BIOTECH Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859562 JANSSEN BIOTECH Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET

More Information on Dosage

AKEEGA family patents

Family Patents

9. Aklief patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7807708 GALDERMA LABS LP Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 04, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 05 October, 2023

Market Authorisation Date: 04 October, 2019

Treatment: NA

Dosage: CREAM

More Information on Dosage

AKLIEF family patents

Family Patents

10. Akynzeo patent expiration

AKYNZEO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9271975 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Sep, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 19, 2023

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 10 October, 2018

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limite...

Dosage: CAPSULE

More Information on Dosage

AKYNZEO family patents

Family Patents

11. Alecensa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9126931 HOFFMANN-LA ROCHE Tetracyclic compound
May, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-756) Nov 06, 2020
New Chemical Entity Exclusivity(NCE) Dec 11, 2020
Orphan Drug Exclusivity(ODE-105) Dec 11, 2022
Orphan Drug Exclusivity(ODE) Nov 06, 2024
Orphan Drug Exclusivity(ODE-159) Nov 06, 2024
New Indication(I-947) Apr 18, 2027
Orphan Drug Exclusivity(ODE-477) Apr 18, 2031

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2019

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE

How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage

ALECENSA family patents

Family Patents

12. Alunbrig patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 28, 2022
New Indication(I-847) May 22, 2023
Orphan Drug Exclusivity(ODE) Apr 28, 2024
Orphan Drug Exclusivity(ODE-142) Apr 28, 2024
Orphan Drug Exclusivity(ODE-300) May 22, 2027

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

ALUNBRIG family patents

Family Patents

13. Angeliq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906890 BAYER HLTHCARE Very low-dosed solid oral dosage forms for HRT
Oct, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Mar 01, 2015

Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient

Market Authorisation Date: 29 February, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of ANGELIQ before it's drug patent expiration?
More Information on Dosage

ANGELIQ family patents

Family Patents

14. Anoro Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2016
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: NA

Dosage: POWDER

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

15. Apadaz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461137 ZEVRA THERAP Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Feb, 2031

(6 years from now)




Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 January, 2019

Treatment: NA

Dosage: TABLET

More Information on Dosage

APADAZ family patents

Family Patents

16. Apretude patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

APRETUDE family patents

Family Patents

17. Armonair Digihaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(6 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
May, 2031

(6 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(6 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(6 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(6 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(6 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(6 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

18. Armonair Respiclick patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(6 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(6 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(6 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(6 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(6 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(6 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARMONAIR RESPICLICK family patents

Family Patents

19. Arnuity Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 20, 2017
New Patient Population(NPP) May 17, 2021
New Strength(NS) May 17, 2021
M(M-290) Mar 01, 2026

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 17 May, 2018

Treatment: NA

Dosage: POWDER

More Information on Dosage

ARNUITY ELLIPTA family patents

Family Patents

20. Aubagio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735

(Pediatric)

SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 12, 2017
M(M-61) Apr 30, 2024
Pediatric Exclusivity(PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

NCE-1 date: 31 October, 2023

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage

AUBAGIO family patents

Family Patents

21. Austedo patent expiration

AUSTEDO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-751) Aug 30, 2020
New Chemical Entity Exclusivity(NCE) Apr 03, 2022
Orphan Drug Exclusivity(ODE) Apr 03, 2024
Orphan Drug Exclusivity(ODE-134) Apr 03, 2024
M(M-54) Jun 24, 2024
Pediatric Exclusivity(PED) Dec 24, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

AUSTEDO family patents

Family Patents

22. Austedo Xr patent expiration

AUSTEDO XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(6 years from now)




Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

AUSTEDO XR family patents

Family Patents

23. Avycaz patent expiration

AVYCAZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8471025 ABBVIE Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-738) Jun 22, 2019
New Chemical Entity Exclusivity(NCE) Feb 25, 2020
Generating Antibiotic Incentives Now(GAIN) Feb 25, 2025
New Patient Population(NPP) Dec 20, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 26 February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER

More Information on Dosage

AVYCAZ family patents

Family Patents

24. Balversa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 12, 2024
New Indication(I-930) Jan 19, 2027

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 13 April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic the...

Dosage: TABLET

How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage

BALVERSA family patents

Family Patents

25. Barhemsys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525033 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(6 years from now)

US9545426 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(6 years from now)

US9889118 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 27 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Prevention of post-operative nausea and vomiting

Dosage: SOLUTION

More Information on Dosage

BARHEMSYS family patents

Family Patents

26. Baxdela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7728143 MELINTA Salt and crystalline forms thereof of a drug
Jun, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 19, 2022
New Indication(I-815) Oct 24, 2022
Generating Antibiotic Incentives Now(GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: TABLET; POWDER

More Information on Dosage

BAXDELA family patents

Family Patents

27. Belrapzo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11872214 EAGLE PHARMS Formulations of Bendamustine
Jan, 2031

(6 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11844783 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma

Dosage: SOLUTION

How can I launch a generic of BELRAPZO before it's drug patent expiration?
More Information on Dosage

BELRAPZO family patents

Family Patents

28. Belviq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770455 EISAI INC Administration of an anti-obesity compound to individuals with renal impairment
Aug, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 27 June, 2012

Treatment: Method for chronic weight management in patients with moderate renal impairment who are obese, or overweight and have at least one weight related comorbid condition

Dosage: TABLET

How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage

BELVIQ family patents

Family Patents

29. Belviq Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226471 EISAI INC Modified-release dosage forms of 5-HT2C agonists useful for weight management
Aug, 2031

(6 years from now)

US9770455 EISAI INC Administration of an anti-obesity compound to individuals with renal impairment
Aug, 2031

(6 years from now)

US10463676 EISAI INC Modified-release dosage forms of 5-HT2C agonists useful for weight management
Aug, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: Method for chronic weight management in patients with moderate renal impairment who are obese, or overweight and have at least one weight related comorbid condition; Chronic weight management in adult...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage

BELVIQ XR family patents

Family Patents

30. Bendeka patent expiration

BENDEKA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11844783 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11872214 EAGLE PHARMS Formulations of Bendamustine
Jan, 2031

(6 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-179) Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For use in the treatment of patients with chronic lymphocytic ...

Dosage: SOLUTION

How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage

BENDEKA family patents

Family Patents

31. Besivance patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8481526 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Jan, 2031

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2014

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

NCE-1 date: 28 May, 2013

Market Authorisation Date: 28 May, 2009

Treatment: NA

Dosage: SUSPENSION/DROPS

More Information on Dosage

BESIVANCE family patents

Family Patents

32. Bevespi Aerosphere patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 25, 2019

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED

More Information on Dosage

BEVESPI AEROSPHERE family patents

Family Patents

33. Bevyxxa patent expiration

BEVYXXA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8404724 PORTOLA PHARMS INC Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 23 June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: Inhibiting coagulation

Dosage: CAPSULE

More Information on Dosage

BEVYXXA family patents

Family Patents

34. Binosto patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592195 RADIUS Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
Dec, 2031

(6 years from now)




Drugs and Companies using ALENDRONATE SODIUM ingredient

Market Authorisation Date: 12 March, 2012

Treatment: NA

Dosage: TABLET, EFFERVESCENT

More Information on Dosage

BINOSTO family patents

Family Patents

35. Braftovi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Mar, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-826) Apr 08, 2023
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026
Orphan Drug Exclusivity(ODE-445) Oct 11, 2030

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as detected by an fda-app...

Dosage: CAPSULE

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

36. Brenzavvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10981942 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jun, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10533032 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 20 January, 2027

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET

More Information on Dosage

BRENZAVVY family patents

Family Patents

37. Breo Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 30, 2018
New Indication(I-708) Apr 30, 2018
New Chemical Entity Exclusivity(NCE) May 10, 2018
M(M-202) May 15, 2020
New Patient Population(NPP) May 13, 2026
New Strength(NS) May 13, 2026
Pediatric Exclusivity(PED) Nov 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: NA

Dosage: POWDER

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

38. Breztri Aerosphere patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED

More Information on Dosage

BREZTRI AEROSPHERE family patents

Family Patents

39. Bryhali patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12076403 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US11957753 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US11986527 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US11839656 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 06, 2021

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 06 November, 2018

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION

How can I launch a generic of BRYHALI before it's drug patent expiration?
More Information on Dosage

BRYHALI family patents

Family Patents

40. Bydureon Bcise patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033

(Pediatric)

ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 20, 2020
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

41. Byfavo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(6 years from now)

US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(6 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(6 years from now)

US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(6 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 06, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 06 October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER

More Information on Dosage

BYFAVO family patents

Family Patents

42. Bylvay patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10093697 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(6 years from now)

US10011633 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(6 years from now)

US10487111 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(6 years from now)

US9694018 IPSEN IBAT inhibitors for the treatment of liver disease
Nov, 2031

(6 years from now)

US11732006 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(6 years from now)

US10981952 IPSEN IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-918) Jun 13, 2026
New Chemical Entity Exclusivity(NCE) Jul 20, 2026
Orphan Drug Exclusivity(ODE-363) Jul 20, 2028
Orphan Drug Exclusivity(ODE-436) Jun 13, 2030

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 20 July, 2025

Market Authorisation Date: 20 July, 2021

Treatment: Method of reducing serum bile acids in patients 12 months or older suffering from alagille syndrome (algs); Method of treating cholestatic pruritus in patients 12 months or older suffering from alagil...

Dosage: CAPSULE; CAPSULE, PELLETS

More Information on Dosage

BYLVAY family patents

Family Patents

43. Cabenuva Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-184) Jan 31, 2025
New Patient Population(NPP) Mar 29, 2025
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

CABENUVA KIT family patents

Family Patents

44. Cabometyx patent expiration

Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions
Jul, 2031

(6 years from now)

US10034873 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Product(NP) Apr 25, 2019
New Indication(I-760) Dec 19, 2020
New Indication(I-792) Jan 14, 2022
New Indication(I-854) Jan 22, 2024
New Indication(I-873) Sep 17, 2024
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of advanced renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib

Dosage: TABLET

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

45. Cerdelga patent expiration

CERDELGA's oppositions filed in EPO
CERDELGA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Jan, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 19, 2019
Orphan Drug Exclusivity(ODE) Aug 19, 2021
Orphan Drug Exclusivity(ODE-73) Aug 19, 2021

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

NCE-1 date: 19 August, 2018

Market Authorisation Date: 19 August, 2014

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twic...

Dosage: CAPSULE

How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage

CERDELGA family patents

Family Patents

46. Cleviprex patent expiration

CLEVIPREX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103490 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(6 years from now)

US8658676 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(6 years from now)

US10010537 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 01, 2013

Drugs and Companies using CLEVIDIPINE ingredient

NCE-1 date: 01 August, 2012

Market Authorisation Date: 01 August, 2008

Treatment: NA

Dosage: EMULSION

How can I launch a generic of CLEVIPREX before it's drug patent expiration?
More Information on Dosage

CLEVIPREX family patents

Family Patents

47. Combogesic Iv patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11896567 HIKMA Combination composition
Oct, 2031

(6 years from now)

US11446266 HIKMA Combination composition
Oct, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 17, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient

Market Authorisation Date: 17 October, 2023

Treatment: Method of treating moderate to severe pain in adults as an adjunct to opioid analgesics

Dosage: SOLUTION

More Information on Dosage

COMBOGESIC IV family patents

Family Patents

48. Contrave patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033543 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2031

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

49. Cosela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8598186 PHARMACOSMOS CDK inhibitors
Oct, 2031

(6 years from now)

US8598197 PHARMACOSMOS CDK inhibitors
Oct, 2031

(6 years from now)

US9957276 PHARMACOSMOS CDK inhibitors
Oct, 2031

(6 years from now)

US10189849 PHARMACOSMOS CDK inhibitors
Oct, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189850 PHARMACOSMOS CDK inhibitors
Oct, 2031

(6 years from now)

US11040042 PHARMACOSMOS Transient protection of normal cells during chemotherapy
Oct, 2031

(6 years from now)

US10927120 PHARMACOSMOS CDK inhibitors
Oct, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 12 February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: NA

Dosage: POWDER

More Information on Dosage

COSELA family patents

Family Patents

50. Daklinza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8629171 BRISTOL-MYERS SQUIBB Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Jun, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-161) Feb 05, 2019
New Dosing Schedule(D-162) Feb 05, 2019
New Indication(I-726) Feb 05, 2019
New Indication(I-727) Feb 05, 2019
New Chemical Entity Exclusivity(NCE) Jul 24, 2020

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

NCE-1 date: 25 July, 2019

Market Authorisation Date: 24 July, 2015

Treatment: Method of inhibiting hepatitis c virus

Dosage: TABLET

More Information on Dosage

DAKLINZA family patents

Family Patents

51. Daurismo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 21, 2023
Orphan Drug Exclusivity(ODE-224) Nov 21, 2025

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: 21 November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: TABLET

More Information on Dosage

DAURISMO family patents

Family Patents

52. Dayvigo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 07, 2025
M(M-293) Apr 20, 2026

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: 07 April, 2024

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET

More Information on Dosage

DAYVIGO family patents

Family Patents

53. Delstrigo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-806) Sep 19, 2022
New Chemical Entity Exclusivity(NCE) Aug 30, 2023
New Patient Population(NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 30 August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically...

Dosage: TABLET

More Information on Dosage

DELSTRIGO family patents

Family Patents

54. Docetaxel patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842770 SHILPA Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
Aug, 2031

(6 years from now)




Drugs and Companies using DOCETAXEL ingredient

Market Authorisation Date: 22 December, 2015

Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion

Dosage: INJECTABLE

More Information on Dosage

DOCETAXEL family patents

Family Patents

55. Dovato patent expiration

DOVATO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234985 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Apr 08, 2022
New Indication(I-839) Aug 06, 2023
New Patient Population(NPP) Apr 05, 2027

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: Treatment of hiv infection

Dosage: TABLET

How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage

DOVATO family patents

Family Patents

56. Drospirenone patent expiration

DROSPIRENONE's oppositions filed in EPO
Can you believe DROSPIRENONE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US11351122 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(6 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(6 years from now)

US11478487 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US11951213 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US12090231 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(6 years from now)

US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(6 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US10987364 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 29, 2025

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET, CHEWABLE

More Information on Dosage

DROSPIRENONE family patents

Family Patents

57. Dsuvia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945592 VERTICAL PHARMS Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 02, 2021

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET

More Information on Dosage

DSUVIA family patents

Family Patents

58. Duobrii patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11986527 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US12076403 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US11839656 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)

US11957753 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 25, 2022

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION

How can I launch a generic of DUOBRII before it's drug patent expiration?
More Information on Dosage

DUOBRII family patents

Family Patents

59. Durysta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8629185 ABBVIE 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 04, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: NA

Dosage: IMPLANT

More Information on Dosage

DURYSTA family patents

Family Patents

60. Duzallo patent expiration

Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216179 IRONWOOD PHARMS INC Treatment of gout and hyperuricemia
Aug, 2031

(6 years from now)

US9956205 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Dec, 2031

(6 years from now)




Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET

More Information on Dosage

DUZALLO family patents

Family Patents

61. Ecoza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071054 RESILIA PHARMS Econazole composition and methods of treatment therewith
Aug, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Oct 24, 2016

Drugs and Companies using ECONAZOLE NITRATE ingredient

Market Authorisation Date: 24 October, 2013

Treatment: NA

Dosage: AEROSOL, FOAM

More Information on Dosage

ECOZA family patents

Family Patents

62. Edarbyclor patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387249 AZURITY Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 20, 2014
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET

How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage

EDARBYCLOR family patents

Family Patents

63. Edluar patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Feb, 2031

(6 years from now)




Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET

How can I launch a generic of EDLUAR before it's drug patent expiration?
More Information on Dosage

EDLUAR family patents

Family Patents

64. Eliquis patent expiration

ELIQUIS's oppositions filed in EPO
ELIQUIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945 BRISTOL MYERS SQUIBB Apixaban formulations
Feb, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-681) Mar 03, 2017
New Indication(I-661) Aug 21, 2017
New Indication(I-690) Aug 21, 2017
New Indication(I-691) Aug 21, 2017
New Chemical Entity Exclusivity(NCE) Dec 28, 2017

Drugs and Companies using APIXABAN ingredient

NCE-1 date: 28 December, 2016

Market Authorisation Date: 28 December, 2012

Treatment: NA

Dosage: TABLET

How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage

ELIQUIS family patents

Family Patents

65. Enstilar patent expiration

ENSTILAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10682364 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(6 years from now)

US9566286 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(6 years from now)

US10617698 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(6 years from now)

US10688108 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(6 years from now)

US10716799 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(6 years from now)

US10130640 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(6 years from now)

US10660908 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(6 years from now)

US9119781 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(6 years from now)

US9119781

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(6 years from now)

US10130640

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 16, 2018
New Patient Population(NPP) Jul 30, 2022
Pediatric Exclusivity(PED) Jan 30, 2023

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Market Authorisation Date: 16 October, 2015

Treatment: Topical treatment of plaque psoriasis in patients 12 years and older

Dosage: AEROSOL, FOAM

How can I launch a generic of ENSTILAR before it's drug patent expiration?
More Information on Dosage

ENSTILAR family patents

Family Patents

66. Epclusa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(6 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 28, 2021
New Dosing Schedule(D-177) Nov 15, 2022
New Patient Population(NPP) Mar 19, 2023
New Strength(NS) Mar 19, 2023
M(M-264) Jul 14, 2023
M(M-277) Apr 27, 2025
Orphan Drug Exclusivity(ODE-293) Mar 19, 2027
Orphan Drug Exclusivity(ODE-376) Jun 10, 2028
Pediatric Exclusivity(PED) Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: NA

Dosage: PELLETS; TABLET

More Information on Dosage

EPCLUSA family patents

Family Patents

67. Evzio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

US10143972 KALEO INC Ultrafiltration membrane and a preparation method thereof
May, 2031

(6 years from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION

More Information on Dosage

EVZIO family patents

Family Patents

68. Evzio (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(6 years from now)

US10143792 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
May, 2031

(6 years from now)

US10143972 KALEO INC Ultrafiltration membrane and a preparation method thereof
May, 2031

(6 years from now)




Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

69. Fanapt patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072742 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Jan, 2031

(5 years from now)

US9074256 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Feb, 2031

(6 years from now)

US9074254 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Dec, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 06, 2014
M(M-180) May 26, 2019
New Indication(I-939) Apr 02, 2027

Drugs and Companies using ILOPERIDONE ingredient

NCE-1 date: 06 May, 2013

Market Authorisation Date: 06 May, 2009

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET

How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage

FANAPT family patents

Family Patents

70. Fetzima patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481598 ABBVIE Stable dosage forms of levomilnacipran
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
NCE*(NCE*) Jul 25, 2018
M(M-249) Oct 07, 2022
M(M-304) Mar 24, 2026

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of FETZIMA before it's drug patent expiration?
More Information on Dosage

FETZIMA family patents

Family Patents

71. Flyrcado patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9603951 GE HLTHCARE Methods and apparatus for synthesizing imaging agents, and intermediates thereof
May, 2031

(6 years from now)

US8936777 GE HLTHCARE Methods and apparatus for synthesizing imaging agents, and intermediates thereof
Jun, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 27, 2029

Drugs and Companies using FLURPIRIDAZ F-18 ingredient

NCE-1 date: 27 September, 2028

Market Authorisation Date: 27 September, 2024

Treatment: Method of positron emission tomography (pet) for cardiac imaging

Dosage: SOLUTION

More Information on Dosage

FLYRCADO family patents

Family Patents

72. Galafold patent expiration

Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48608 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases
Oct, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 10, 2023
Orphan Drug Exclusivity(ODE-205) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE

How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage

GALAFOLD family patents

Family Patents

73. Gelnique patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8920392 ABBVIE Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Mar, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jan 27, 2012

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin

Dosage: GEL

How can I launch a generic of GELNIQUE before it's drug patent expiration?
More Information on Dosage

GELNIQUE family patents

Family Patents

74. Giapreza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572856 LA JOLLA PHARMA Method of treating low blood pressure
Jul, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 21 December, 2021

Market Authorisation Date: 23 December, 2021

Treatment: Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor

Dosage: SOLUTION

How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage

GIAPREZA family patents

Family Patents

75. Giazo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497256 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
Jun, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Feb 03, 2015

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 03 February, 2012

Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients

Dosage: TABLET

How can I launch a generic of GIAZO before it's drug patent expiration?
More Information on Dosage